Company intelligence / Profile preview

PainReform

Ownership: Public · PRFX
Development stage: Phase 3

Overview

The lead candidate, PRF‑110, demonstrated a solid safety profile with no serious adverse events in early Phase III trials for bunionectomy patients. Plasma concentrations were well below FDA safety thresholds. However, the company encountered a temporary setback due to a data gap in the final phase of its Phase III trial and has initiated further R&D to address this before resuming clinical work.

Therapeutic areas: OtherGastroenterologyNeurology
Modalities: Small moleculeOil-based drug delivery system
Industry: Biotech

Drug pipeline

3 assets

PRF-110

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $74.7K
Total revenue: $17K
Enterprise value: $-4M

Beyond the preview

Go deeper on PainReform.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PainReform.

Explore the full profile